Estimating the Financial Impact of Introducing Glycopyrronium Bromide in the Treatment of Chronic Obstructive Pulmonary Disease (Copd) From the Perspective of Public Payer of São Paulo (Sp) – Brazil
Abstract
Authors
C Suzuki N Lopes